Accessibility Menu
VolitionRx logo

VolitionRx(NYSEMKT) VNRX

Market Cap$9.58MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)-99%
5 Year-99%
1 Year-94%
1 Month-41%
$0.76
-4.09%
-0.03Today
VolitionRx last closing stock price
MetricPriceDate
Last closeUSD 0.802026-08-05
VolitionRx stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2.9%USD 0.772026-07-29
1 month-41.11%USD 1.352026-07-06
3 month-67.15%USD 2.422026-05-07
Year to date-84.45%USD 5.112025-12-31
1 year-93.79%USD 12.802025-08-05
3 year-96.94%USD 26.002023-08-04
5 year-98.75%USD 63.402021-08-06
Since inception-98.67%USD 60.002011-10-07

VolitionRx Financials at a Glance

Market Cap

$9.58MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.47M

Net Income (TTM)

-$24.60M

EPS (TTM)

-$4.21

P/E Ratio

-0.19

Dividend

$0.00

Beta (Volatility)

0.78 (Low)

Price

$0.76

Volume

384,898.313

Open

$0.79

Previous Close

$0.80

Daily Range

$0.74 - $0.81

52-Week Range

$0.69 - $15.10

Estimated Earnings Date

Aug 13, 2026

VNRX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About VolitionRx

VolitionRx develops blood tests that help detect cancer and other diseases early. Its products support both human healthcare and animal health, making diagnosis simpler for doctors and veterinarians. These tests aim to provide faster answers for patients and pet owners.

Products and Services

  • Nu.Q Vet Cancer Test: Blood test for early cancer detection in dogs; main revenue driver (exact percentage not disclosed).
  • Nu.Q NETs: Test for diseases linked to immune system activity, such as sepsis, used in hospitals and labs.
  • Nu.Q Discover: Platform for profiling nucleosomes (DNA-protein structures) to support drug research and development.
  • Nu.Q Cancer: Blood-based tests for cancer screening, diagnosis, and monitoring, with a focus on lung cancer.
  • Capture-Seq / Capture-PCR: Tools for isolating tumor DNA from blood, aiding in cancer detection and monitoring.

Growth and Expansion

  • Expanded Nu.Q Vet Cancer Test to cats in 2025, broadening veterinary reach.
  • Formed automation partnership with Fujifilm Vet Systems in 2025 for high-volume veterinary testing.
  • Launched first regulated Nu.Q NETs product in Europe in Q1 2025, marking entry into automated hospital diagnostics.
  • Signed new distribution and co-marketing deals with Werfen, Hologic, and Revvity in 2025.
  • Invested in new R&D and production facilities in Belgium and an innovation lab in California in 2025.

What Makes VolitionRx Stand Out

VolitionRx operates globally, selling through established partners in over 20 countries. Its technology detects disease by analyzing changes in nucleosomes, a key part of DNA packaging. The company holds a large patent portfolio, supporting its licensing and partnership strategy.

Five Things You Need to Know

  • Revenue was $1.7 million in 2025, up 40% from 2024.
  • Net loss was $23.5 million in 2025, improving 14% from 2024.
  • Cash and equivalents were $1.1 million at year-end 2025, down from 2024.
  • Deferred revenue reached $21.9 million in 2025, mainly from licensing deals.
  • Three largest customers made up over 43% of 2025 sales.

Bottom Line

VolitionRx has diversified into both human and animal diagnostics, focusing on early disease detection. The company continues to adapt through partnerships, new products, and global expansion.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

75

CEO

Cameron John Reynolds, MBA

Website

www.volition.com

Headquarters

Henderson, NV 89014, US

VNRX Financials

Key Financial Metrics (TTM)

Gross Margin

89.68%

Operating Margin

-870.98%

Net Income Margin

-997.46%

Return on Equity

74.16%

Return on Capital

N/A

Return on Assets

-272.21%

Earnings Yield

-5.26%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$9.58MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

12.04M

Volume

384.90K

Avg. Volume

462.01K

Financials (TTM)

Gross Profit

$2.21M

Operating Income

-$21.48M

EBITDA

-$20.60M

Operating Cash Flow

-$20.51M

Capital Expenditure

-$95.79K

Free Cash Flow

-$20.60M

Cash & ST Invst.

$3.10M

Total Debt

$11.42M

VolitionRx Performance Analysis

VolitionRx annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 306,392240.3%
20232023-12-31USD 775,302153.0%
20242024-12-31USD 1,233,51159.1%
20252025-12-31USD 1,727,38440.0%
VolitionRx sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3065.1%
Q32025-09-3054.2%
Q42025-12-31-28.7%
Q12026-03-31120.4%
VolitionRx annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -10.947.4%
20232023-12-31USD -9.92-9.3%
20242024-12-31USD -6.23-37.1%
20252025-12-31USD -4.37-29.8%
VolitionRx sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-8.9%
Q32025-09-3018.3%
Q42025-12-31-5.0%
Q12026-03-317.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$985.08K

+299.8%

Gross Profit

$730.67K

+196.6%

Gross Margin

74.17%

N/A

Market Cap

$9.58MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$127.67K

N/A

Employees

75

N/A

Net Income

-$6.66M

-22.9%

EBITDA

-$5.87M

-15.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$3.10M

+19.3%

Total Debt

$11.42M

+55.0%

Accounts Receivable

$252.24K

+34.3%

Inventory

$0.00

N/A

Long Term Debt

$6.86M

+10.0%

Short Term Debt

$4.56M

+301.7%

Return on Assets

-2.72%

N/A

Return on Invested Capital

4.46%

N/A

Free Cash Flow

-$5.29M

-23.0%

Operating Cash Flow

-$5.28M

-22.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
WGRXWellgistics Health, Inc.
$3.52+0.00%
MDCXMedicus Pharma Ltd. Common Stock
$0.32+7.24%
NOTVInotiv, Inc.
$0.08+121.94%
SKYESkye Bioscience, Inc.
$0.58+3.26%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$110.99+0.03%
CLROClearOne
$9.02+1.45%
SOUNSoundHound AI
$7.19+0.12%
NVDANvidia
$217.96-0.01%

Questions About VNRX

What is the current price of VolitionRx?

VolitionRx is trading at $0.77 per share.

What is the 52-week range for VolitionRx?

Over the past 52 weeks, VolitionRx has traded between $0.69 and $15.10.

How much debt does VolitionRx have?

As of the most recent reporting period, VolitionRx reported total debt of $11.70M.

How much cash does VolitionRx have on hand?

VolitionRx reported $3.10M in cash and cash equivalents in its most recent financial results.

What is VolitionRx’s dividend yield?

VolitionRx does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services